Evidence map›Paper›PMID 35736346›Full record

ArticleMedical sciences (Basel, Switzerland)2022

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.

Charlotte Andrieu, Niamh McNamee, Anne-Marie Larkin, Alanna Maguire, Roopika Menon, Judith Mueller-Eisert, Noel Horgan, Susan Kennedy, Giuseppe Gullo, John Crown and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Charlotte AndrieuNational Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, D09 E432 Dublin, Ireland.ORCID 0000-0002-7761-5025
Niamh McNameeNational Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, D09 E432 Dublin, Ireland.
Anne-Marie LarkinNational Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, D09 E432 Dublin, Ireland.
Alanna MaguireNational Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, D09 E432 Dublin, Ireland.ORCID 0000-0002-1193-5528
Roopika MenonSiemens Healthcare Diagnostics Products GmbH, 50667 Cologne, Germany.
Judith Mueller-EisertSiemens Healthcare Diagnostics Products GmbH, 50667 Cologne, Germany.
Noel HorganRoyal Victoria Eye and Ear Hospital, Adelaide Road, D02 XK51 Dublin, Ireland.
Susan KennedyRoyal Victoria Eye and Ear Hospital, Adelaide Road, D02 XK51 Dublin, Ireland.
Giuseppe GulloDepartment of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
John CrownDepartment of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
Naomi WalshNational Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, D09 E432 Dublin, Ireland.ORCID 0000-0002-2178-3564
Dublin City University · IERoyal Victoria Eye and Ear Hospital · IESiemens Healthineers (Germany) · DESt. Vincent's University Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular and histopathological analysis of melanoma subtypes has revealed distinct epidemiological, genetic, and clinical features. However, immunotherapy for advanced metastatic melanoma patients does not differ based on subtype. Response to immune checkpoint inhibitors (ICI) has been shown to vary, therefore, predictive biomarkers are needed in the design of precision treatments. Targeted sequencing and histopathological analysis (CD8 and CD20 immunohistochemistry) were performed on subtypes of metastatic melanoma (cutaneous melanoma (CM,

Indexed as

MelanomaNeoplasms, Second PrimarySkin NeoplasmsCutaneous Malignant MelanomaDNA DamageHumansImmune Checkpoint InhibitorsMutationImmune Checkpoint Inhibitorsacral lentiginous melanomacutaneous melanomagenomicshead and neck melanomaimmunotherapymucosal melanomaprecision medicinepredictive biomarkerstargeted sequencinguveal melanoma

Identifiers

PMID35736346
PMCPMC9230974
OpenAlexW4281385788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.